New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss
GlobeNewswire, 23 Apr 2014
Accessed on 17 May 2014 from http://www.nasdaq.com/press-release/new-data-at-aan-to-confirm-efficacy-of-novartis-gilenya-across-four-key-measures-of-ms-disease-20140423-00020.